Guidance, NICE advice and quality standards in development | Guidance

Showing 411 to 420 of 437

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and TA862) [ID5121]	Technology appraisal guidance	7 May 2026
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]	Technology appraisal guidance	TBC
Triheptanoin for treating long-chain fatty acid oxidation disorders [ID3891]	Technology appraisal guidance	TBC
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]	Technology appraisal guidance	TBC
Type 2 diabetes in adults: management (medicines update)	NICE guideline	18 February 2026
Upadacitinib for treating giant cell arteritis [ID6299]	Technology appraisal guidance	TBC
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]	Technology appraisal guidance	TBC
Venetoclax with azacitidine for treating acute myeloid leukaemia before and after an allogeneic stem cell transplant [ID6468]	Technology appraisal guidance	TBC
Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]	Technology appraisal guidance	TBC
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]	Technology appraisal guidance	TBC